Lung cancer treatment and research at Dana-Farber
While lung cancer will make up only 15 percent of the cases of cancer that are expected to be diagnosed in 2007, it will account for nearly 30 percent of all cancer-related deaths. Incidence and mortality rates, however, are now decreasing in men and stabilizing in women, a fact that can be attributed to decreased smoking rates over the past 30 years, according to the American Cancer Society.
Related Stories
- Genome study charts genetic landscape of lung cancer (Nov. 4, 2007)
- Multi-center study nets new lung tumor-suppressor gene (Aug. 6, 2007)
- Black Americans' beliefs may hamper lung cancer prevention and care (June 4, 2007)
- New mechanism identified for resistance to targeted lung cancer drugs (April 26, 2007)
- Study reveals how some molecules inhibit growth of lung cancer cells (March 12, 2007)
- Study uncovers mechanism of drug resistance in form of lung cancer (Sept. 7, 2006)
- It's never too late to quit smoking (Nov. 16, 2005)
- Study finds Tarceva® benefits older lung cancer patients (Sept. 19, 2005)
- Two designer drugs hit same lung cancer target, but only one is effective (Aug. 17, 2005)
- Lung cancer can strike anyone, but smokers at greatest risk (Aug. 15, 2005)
- DNA-scanning technology finds possible sites of cancer genes in chromosomes of lung cancer cell (July 1, 2005)
- High-powered gene profiles provide new clues to genes involved in common form of lung cancer (June 27, 2005)
- Dana-Farber researchers receive CDC grants to develop health promotion and prevention programs in the work place (Nov. 2, 2004)
- Patient and physician attitudes may deter African Americans from receiving surgery for non-small cell lung cancer, study finds (June 5, 2004)
- Study identifies which patients can benefit from targeted lung cancer drug - and why (April 29, 2004)
Related Links
Mesothelioma Surgery Webcast
Surgeons from Dana-Farber/Brigham and Women's Cancer Center last spring demonstrated a type of cancer surgery called extrapleural pneumonectomy that generally extends the lives of patients stricken by mesothelioma, an aggressive form of cancer most often associated with exposure to asbestos. The surgery was performed by David Sugarbaker, MD, a pioneer in this complex surgical technique. Learn more

